GENE ONLINE|News &
Opinion
Blog

Orphan Drug Designation
The U.S. FDA Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of DMD
2023-08-17
South Korea Puts Everest Medicines’ Nefecon On Fast Track
2023-02-10
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
BioCryst’s ALK-2 Inhibitor Granted FDA Orphan Drug Status For Rare Bone Disease
2022-09-01
Three Companies Received Orphan Drug Designations in One Day To Treat Rare Cancers
2022-06-20
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
2022-03-29
GC Pharma’s Enzyme Replacement Therapy Wins Orphan Drug Designation from EMA
2021-11-02
R&D
BARDA Funds Development of Live Biotherapeutic Product Against C. difficile Infections
2020-10-05
Gilead Requests FDA to Rescind Remdesivir’s Orphan Drug Designation
2020-03-25
Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment
2020-03-24
Pfizer Collaborates with Vivet to Develop Gene Therapy for Wilson Disease
2019-03-29
LATEST
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top